Valganciclovir hydrochloride
|
|
|
- CAS-Nr.
- 175865-59-5
- Englisch Name:
- Valganciclovir hydrochloride
- Synonyma:
- VALGANCICLOVIR HCL;Valcyte;Valcyt;Rs 079070-194;25MG/100MG/1KG;Unii-4p3T9qf9nz;Ro 107-9070/194;Valgancyclovir HCL USP;Valganciclovir hydrochlorid;Valganclicovir hydrochlcnde
- CBNumber:
- CB0380410
- Summenformel:
- C14H23ClN6O5
- Molgewicht:
- 390.82
- MOL-Datei:
- 175865-59-5.mol
|
Valganciclovir hydrochloride Eigenschaften
- Schmelzpunkt:
- 162-164°C
- storage temp.
- Keep in dark place,Inert atmosphere,2-8°C
- L?slichkeit
- H2O: ≥8mg/mL
- Aggregatzustand
- powder
- Farbe
- white to tan
- Stabilit?t:
- Hygroscopic
- InChIKey
- ZORWARFPXPVJLW-MTFPJWTKSA-N
- CAS Datenbank
- 175865-59-5
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| WGK Germany |
3 |
|
|
| HS Code |
2933595960 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H312 |
Gesundheitssch?dlich bei Hautkontakt. |
Akute Toxizit?t dermal |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P280,P302+P352, P312, P322, P363,P501 |
| H332 |
Gesundheitssch?dlich bei Einatmen. |
Akute Toxizit?t inhalativ |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P271, P304+P340, P312 |
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P271 |
Nur im Freien oder in gut belüfteten R?umen verwenden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P304+P340 |
BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen. |
| P330 |
Mund ausspülen. |
| P363 |
Kontaminierte Kleidung vor erneutem Tragen waschen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Valganciclovir hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Valganciclovir hydrochloride, a prodrug of the antiviral ganciclovir, was launched in the
US for the oral treatment of cytemegalovirus (CMV) retinitis, a sight-threatening
complication in patients with AIDS. This L-Valyl ester prodrug can be prepared in three
steps from the nucleoside analog ganciclovir by trimethylsilyl-protection of the amino
group, coupling with N-benzyloxycarbonyl-L-valine-N-carboxyanhydride, hydrolysis with
hydrochloric acid and hydrogenolysis of the Cbz-protecting group. Valganciclovir is well
absorbed and rapidly hydrolyzed to ganciclovir by intracellular esterases in the intestinal
mucosal cells and by hepatic esterases. Unlike ganciclovir, valganciclovir was
demonstrated to be actively transported by the intestinal peptide transporter PEPT1 in
Caco-2 cells. As a consequence, its absolute bioavailability in human was 10-fold higher
compared to ganciclovir (6%). In clinical trials, it was shown that a twice-daily 900 mg dose
of valganciclovir resulted in similar systemic ganciclovir exposure to 5 mg/kg twice-daily
intravenous injection of ganciclovir. Valganciclovir concentrations could not be quantified in
most patients within three to four hours. In a randomized non-blind phase III clinical trial,
oral valganciclovir (900 mg twice daily for three weeks then 900 mg once daily for one
week) was as effective as intravenous ganciclovir (5 mg/kg twice daily for three weeks
then 5 mg/kg once daily). Oral treatment with valganciclovir avoided catheter-related
infection that sometimes occurred with intravenous ganciclovir.
Chemische Eigenschaften
White Crystalline Solid
Verwenden
Valganciclovir hydrochloride hydrate may be used in HIV-related cell signaling studies.
Allgemeine Beschreibung
Valganciclovir Hydrochloride is the L-valyl ester of ganciclovir and an antiviral drug, widely used to treat cytomegalovirus infections.
Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to pharmacopeia primary standards.
Nebenwirkungen
Side effects of Valganciclovir hydrochloride include: leukopenia, neutropenia, anaemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anaemia. Based on animal data and limited human data, Valganciclovir Oral Solution may temporarily or permanently inhibit spermatogenesis in males and inhibit fertility in females, which in turn may lead to birth defects in humans. It may also cause cancer in humans.
Valganciclovir hydrochloride Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Valganciclovir hydrochloride Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 393)Lieferanten
175865-59-5()Verwandte Suche:
- L-Valine,2-[(2-aMino-1,6-dihydro-6-oxo-9H-purin-9-yl)Methoxy]-3-hydroxypropyl ester,hydrochloride (1:1)
- 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]-3-hydroxypropyl (2S)-2-amino-3-methylbutanoate hydrochloride hydrate
- L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, monohydrochloride hydrate
- Valganciclovir hydrochloride hydrate
- Rs 079070-194
- Unii-4p3T9qf9nz
- Valcyt
- Valganciclovir hydrochlorid
- Valganciclovir Hydrochloride (500 mg)
- 2-[(2-AMino-1,6-dihydro-6-oxo-9H-purin-9-yl)Methoxy]-3-hydroxypropyl Ester
- 25MG/100MG/1KG
- 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7- dihydro-3H-imidazo[4,5-d]pyrimidin-7-one hydrochloride
- L-Valine,2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, hydrochloride
- VALGANCICLOVIR HYDROCHLORIDE
- L-VALINE, 2-[(2-AMINO-1,6-DIHYDRO-6-OXO-9H-PURIN-9-YL)METHOXY]-3-HYDROXYPROPYL ESTER, MONOHYDROCHLORIDE
- L-VALINE,2-[(2-AMINO-1,6-DIHYDRO-6-OXO-9H-PURIN-9-YL)METHOXY]-3-HYDROXYPROPYLESTER,MONOHYDROCHLORIDE
- Ro 107-9070/194
- 2-((2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy)-3-hydroxypropyl L-valinate hydrochloride
- Valgancyclovir hydrochloride
- Valganciclovir-d5 HCl (Mixture of Diastereomers)
- Valganciclovir hydrochloric acid
- Valganciclovir HCl (Mixture of Diastereomers)
- Valganciclovir hydrochloride USP/EP/BP
- Valganciclovir hydrochloride (API)
- Valganciclovir D5 hydrochlorideQ: What is
Valganciclovir D5 hydrochloride Q: What is the CAS Number of
Valganciclovir D5 hydrochloride Q: What is the storage condition of
Valganciclovir D5 hydrochloride Q: What are the applications of
Valganciclovir D5 hydrochloride
- ValganciclovirHydrochlorideQ: What is
ValganciclovirHydrochloride Q: What is the CAS Number of
ValganciclovirHydrochloride Q: What is the storage condition of
ValganciclovirHydrochloride Q: What are the applications of
ValganciclovirHydrochloride
- Valganciclovir Hydrochloride (1708004)
- (2S)-2-((2-Amino-6-oxo-1H-purin-9(6H)-yl)methoxy)-3-hydroxypropyl 2-amino-3-methylbutanoate hydrochloride
- Valcyte
- VALGANCICLOVIR HCL
- Valganciclovir hydrochloride salt hydrate
- Valganciclovir Hydrochloride
L-Valine 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-
3-hydroxy propyl ester hydrochloride
- 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxy-propyl] (2S)-2-amino-3-methyl-butanoate
- Valgancyclovir HCL USP
- Valganclicovir hydrochlcnde
- 175865-59-5
- C14H22N6O5HCl
- C14H22N6O5ClH
- Pharmaceuticals
- Bases & Related Reagents
- Intermediates & Fine Chemicals
- Nucleotides
- CLEOCIN
- API
- 175865-59-5
